ArticleFrontiers in oncology2023

Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients.

Jizheng Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.